

## **SUPPLEMENTARY INFORMATION**

### **Distinct pseudokinase domain conformations underlie divergent activation mechanisms among vertebrate MLKL orthologs**

Davies et al.

**Supplementary Table 1. X-ray crystallography data collection and refinement statistics**

	Rat MLKL (179-464)	Horse MLKL (188-475)
Data collection		
Space group	P 6 <sub>1</sub> 2 2	C 2
Cell dimensions		
<i>a</i> , <i>b</i> , <i>c</i> (Å)	190.0, 190.0, 77.79	155.5, 124.8, 81.05
$\alpha$ , $\beta$ , $\gamma$ (°)	90, 90, 120	90, 112.7, 90
Resolution (Å)	47.5 – 2.19 (2.27 – 2.19)	40.1 – 2.75 (2.84 – 2.75)
R-merge	0.1024 (1.24)	0.1914 (1.548)
<i>I</i> / $\sigma$ <i>I</i>	24.83 (3.04)	8.79 (0.99)
Completeness (%)	100 (98)	99 (90)
Redundancy	20.2 (20.3)	6.9 (6.2)
Refinement		
Reflections used in refinement	42667 (4080)	36830 (3346)
R-work	0.1852 (0.2348)	0.1834 (0.3138)
R-free	0.2161 (0.2913)	0.2379 (0.3601)
No. non-hydrogen atoms		
Protein	4300	6645
Ligand	4112	6585
Water	6	12
	182	48
Average B-factor		
Protein	51.33	59.53
Ligand	51.21	59.44
Water	91.83	65.59
	52.50	45.13
R.M.S. deviations		
Bond lengths (Å)	0.01	0.01
Bond angles (°)	1.02	1.38

Statistics for the highest-resolution shell are shown in parentheses.

## SUPPLEMENTARY FIGURES

### **Supplementary Figure 1. Amino acid sequence alignments for MLKL orthologs examined in this work.**

Sequence alignment of orthologs with Linnaean names on the left and common names on the right. Residues conserved with identity (dark green) and high similarity (light green) are highlighted in the alignment. Regions equivalent to catalytic motifs on canonical kinases are coloured red, and residues of the  $\alpha$ C helix (dark blue) and activation loop (light blue) are highlighted. The position of the horse  $\beta$ 3- $\alpha$ C loop helix is indicated in bright blue, and the residues equivalent to RIPK3 binding residue (F373 in mouse) are highlighted in yellow. The domain architecture of mouse MLKL (PDB:4BTFF) is illustrated above the alignment: lines are loops, cylinders are helices and arrows  $\beta$ -sheets. Underlined, bolded residues are RIPK3 substrates in mouse and human MLKL. Residue numbering corresponds to the mouse MLKL sequence.




**Supplementary Figure 2. An example of the flow cytometry gating strategy used throughout this study.**

Intact cells were gated as shown in (a). Subsequently, viability was measured based on propidium iodide (PI)-uptake (b), where PI uptake identified dead cells. This strategy has is as previously reported<sup>1</sup>.


**a Gate intact cells**

e.g. *Mlkl*<sup>-/-</sup> MDF + Horse MLKL  
uninduced, untreated



**b Gate PI positive cells**



e.g. *Mlkl*<sup>-/-</sup> MDF + Horse MLKL




**Supplementary Figure 3. Western blot validation of MLKL ortholog and mutant expression in *Mlkl*<sup>-/-</sup> mouse dermal fibroblasts (MDF) and *MLKL*<sup>-/-</sup> U937 human cells.**

(a) Doxycycline-induced expression of mouse, human, horse, rat, tuatara, chicken, stickleback, pig and frog MLKL in *Mlkl*<sup>-/-</sup> MDF cells was validated by western blot using the anti-MLKL mAb (clone 3H1), via a C-terminally fused FLAG tag or using another anti-MLKL mAb (clone 5C4) for pig MLKL. Exogenes were expressed in MDF lines derived from biologically-independent *Mlkl*<sup>-/-</sup> mice (denoted 391, 392 and 393). GAPDH blots were used as loading controls. (b) Expression of orthologs in *MLKL*<sup>-/-</sup> human U937 cells was monitored by western blot as for MDF cells in (a). Note tuatara MLKL expression was not detectable in U937 cells. (c, d) Expression of horse and mouse MLKL mutants in *Mlkl*<sup>-/-</sup> MDF cells was monitored by western blot as described in (a). (e) Rat S345D mutant MLKL expression in *Mlkl*<sup>-/-</sup> MDF and *MLKL*<sup>-/-</sup> U937 cells was validated with the pan-MLKL mAb (3H1 clone) by western blot. The positions of molecular weight markers are shown on the left in each panel. The shown western blots are representative of 2 independent repeats. Uncropped blots are provided in a Source Data file.


### a Orthologs in *Mlkl*<sup>-/-</sup> MDF cells




### d Mouse MLKL F373A in *Mlkl*<sup>-/-</sup> MDF cells





### b Orthologs in *MLKL*<sup>-/-</sup> U937 cells



### e Rat S345D mutant




### c Horse MLKL mutants *Mlkl*<sup>-/-</sup> MDF cells



#### Supplementary Figure 4. Electron density maps for the novel activation loop conformation of horse MLKL.

Electron density maps for the activation loop and surrounding regions of the horse MLKL pseudokinase structure for all three chains of the asymmetric unit. The blue mesh shows the  $\sigma$  weighted 2Fo-Fc refined density, and the red and green mesh show the difference density map, Fo-Fc. Bonds are depicted as lines; green for carbon atoms, red for oxygen and blue for nitrogen. Thr356 and Ser357, the activation loop residues equivalent to those targeted by RIPK3 in human MLKL, and the N- and C-lobes, are labelled. The 2Fo-Fc density was contoured at 1.0  $\sigma$  and Fo-Fc density contoured at 3.5  $\sigma$ . Maps were visualised in Coot<sup>2</sup>.





### Supplementary References

1. Murphy JM, *et al.* The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. *Immunity* **39**, 443-453 (2013).
2. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486-501 (2010).